DSM Says EBITDA Up 19% in 2Q

August 6 (Bloomberg) -- Royal DSM CEO Feike Sijbesma discusses DSM earnings and how they've built on the momentum from the first quarter. He speaks with Mark Barton on Bloomberg Television's "Countdown." (Source: Bloomberg)
Shire Makes $30B All-Stock Bid for Drug Maker Baxalta
38:47 - Shire makes a $30B all-stock bid for one month old Baxalta. So what would this deal mean for the industry? Bloomberg Intelligence’s Sam Fazeli discusses the deal on “Countdown.” (Source: Bloomberg)
  • Greece Sees Bailout in Sight
  • Supply vs. Demand: The Perfect Storm in Commodities
  • Commodities Slide: Should You Brace for the Worst?